Introduction {#Sec1}
============

Clinical trials have shown that it is possible to successfully restore host immunity against various malignant neoplasms even in advanced stage disease by deploying drugs that target the PD-1/PD-L1 axis \[[@CR1]--[@CR5]\]. In most of these studies, higher expression of PD-L1 was associated with a more robust clinical response, suggesting that detection of PD-L1 expression could be used as predictive biomarker. However, anti-PD1/PD-L1 therapy companies developed distinct immunohistochemistry protocols for assessing a single biomarker (PD-L1 expression), as well as different scoring schemes for the readouts. The latter include differences in the cell type assessed for the expression and different cut-off points as thresholds \[[@CR2]--[@CR4]\]. "Intended use" in this context is a part of the so-called "3D" concept, where a "fit-for-purpose" approach to test development and validation establishes explicit links between Disease, Drug, and Diagnostic assay \[[@CR6]\].

Several such fit-for-purpose immunohistochemistry kits are commercially available, but in clinical practice, and especially in publicly funded health care, it is challenging to make all such testing available to patients \[[@CR7]--[@CR9]\]. Because of the great need to simplify testing, either by reducing the number of immunohistochemistry assays being used or the number of interpretative schemes employed or both, many studies have been conducted that compared the analytical performance of the various immunohistochemistry PD-L1 assays to determine if they might be deemed "interchangeable". The concordance in the analytical performance of the immunohistochemistry assays and scoring algorithms derived from these studies have been reviewed by Büttner et al. and Udall et al. respectively \[[@CR7], [@CR10]\]. Although most of these studies have compared different PD-L1 immunohistochemistry assays to one another, there is little guidance on how the results of these studies may be applied clinically.

The goal of this study is to assess the performance of PD-L1 immunohistochemistry assays based on their diagnostic accuracy at specific cut-points, as defined for specific immunotherapies according to the clinical efficacy demonstrated in their respective pivotal clinical trials.

In other words, given an Food add Drug Administration-cleared assay, which other assays can be considered substantially equivalent for that specific purpose? Although comparison of immunohistochemistry assays for their analytical similarities is warranted and useful for clinical immunohistochemistry laboratories, it is an insufficient foundation on which to make an informed decision whether an Food and Drug Administration-approved companion diagnostic with a specific clinical purpose can be replaced by another assay, whether the substitute assay is an Food and Drug Administration-approved companion diagnostic for a different purpose or a laboratory developed test. The more appropriate approach for these qualitative assays would be comparing the results of the candidate assay for its diagnostic accuracy against a comparative method/assay or designated reference standard \[[@CR11]\]. We report here the results of our meta-analyses of 376 assay comparisons from 22 studies for different cut-off points, focusing on the sensitivity and specificity of these tests, based on their intended clinical utility.

Methods {#Sec2}
=======

Methodology including data sources, study selection, data abstraction, and grading evidence, are detailed in Supplementary Files [Methodology](#MOESM2){ref-type="media"}. Modified GRADE and QUADAS-2 criteria were used for grading published evidence and designing data abstraction templates to guide independent extraction by multiple reviewers \[[@CR12]--[@CR15]\]. PRISMA was used to guide reporting of the systematic review and meta-analysis and STARD 2015 for reporting the diagnostic accuracy study \[[@CR16]--[@CR18]\]. CLSI EP12-A2 was used to guide test comparisons \[[@CR11]\] Data were pooled using a random-effects model.

Framework {#Sec3}
---------

A systematic review of literature was conducted as a part of a national project for developing Canadian guidelines for PD-L1 testing. The Canadian Association of Pathologists -- Association canadienne des pathologistes (CAP-ACP) National Standards Committee for High Complexity Testing initiated development of CAP-ACP Guidelines for PD-L1 testing to facilitate introduction of PD-L1 testing for various purposes to Canadian clinical immunohistochemistry laboratories. This review was also used to guide the selection of publications to be used in this meta-analysis.

Purpose-based approach {#Sec4}
----------------------

The purposes identified in the systematic review of published literature were based on either the clinical purpose that was specifically identified in the published study or the intended purpose for which the included specific companion diagnostic assay was clinically validated. Although a large number of potential purposes were identified, only few could be included in this meta-analysis. The selection was based on the type of data available, including which immunohistochemistry protocols and which readout was performed by the authors. The greatest limitation in the accrual of data from these published studies was based on the selection of the readout employed to assess the results; in most studies the readout was limited to tumor proportion score with 1% and 50% cut-offs, which is essentially based on the clinically meaningful cut-offs for pembrolizumab and nivolumab therapy. Hence, these two readouts were selected for our analysis and form the basis for outlining different purposes that are derived from the combination of the readouts and immunohistochemistry kits/protocols that use these readouts and are approved by regulatory agencies (e.g., Food and Drug Administration) for different clinical uses.

Most published studies on PD-L1 test comparison did not include 2 × 2 tables that would allow calculations of either diagnostic sensitivity and specificity or positive percent agreement and negative percent agreement. The CAP-ACP National Standards Committee for High Complexity Testing requested this information from the authors of studies where it was evident that the authors generated such results, but did not include them in their published manuscript. Most studies required generation of multiple 2 × 2 tables, as each one was designed for a specific purpose and set of candidate' and 'comparator' assays. For primary studies that provided sufficient detail, information on study setting, comparative method/reference standard and 2 x 2 tables for different tumor proportion score cut-offs were extracted, from which accuracy results were reported. Studies of PD-L1 immunohistochemistry assay comparisons that did not compare the performance of the assay to any designated or potential reference standard (e.g., where analytical comparison of PD-L1 assays were all laboratory developed tests and/or no specific purpose was identified or where positive percent agreement and negative percent agreement could not be generated from study data) \[[@CR19]--[@CR22]\] were not included in this meta-analysis, because in such studies, diagnostic accuracy for a specific clinical purpose could not be determined. The acquisition of data resulted in cumulative evidence of 376 assay comparisons from 22 published studies \[[@CR6], [@CR23]--[@CR43]\].

Study tissue model(s) {#Sec5}
---------------------

Most studies evaluated PD-L1 immunohistochemistry in non-small cell lung cancer, resulting in 337 test comparisons. Comparisons of test performance in other tumors were much less common. These included analysis of urothelial carcinoma (20 test comparisons), mesothelioma (9 test comparisons) and thymic carcinoma (9 test comparisons).

Meta-analysis {#Sec6}
-------------

Reported or calculated diagnostic accuracy (sensitivity and specificity) from the individual studies were summarized. Random-effects models were fitted \[[@CR44], [@CR45]\]. For the qualitative review, a forest plot was used to obtain an overview of sensitivity and specificity for each study. Cochran's heterogeneity statistics Q and I^2^ were used to examine heterogeneity among studies. Funnel plots and Egger's test were applied to detect possible publication bias (see Supplementary Files for images of [funnel plots](#MOESM5){ref-type="media"}) \[[@CR46], [@CR47]\]. The significance level of 0.05 was set for all analyses. Meta-analysis was performed using software *Strata 15 SE*.

Interpretation of results {#Sec7}
-------------------------

### Clinically acceptable diagnostic accuracy {#Sec8}

For the purpose of this study, the immunohistochemistry candidate assays were considered to be acceptable for clinical applications if both sensitivity and specificity for the stated clinical purpose/application were ≥90% \[[@CR48]\].

### Applicability of meta-analysis results: Food and Drug Administrtion-approved immunohistochemistry kits vs. laboratory developed tests {#Sec9}

Assuming that laboratories follow the instructions for use provided with Food and Drug Administration-approved or European CE-marked immunohistochemistry kits, the overall results of this meta-analysis could be considered highly representative and generalizable of Food and Drug Administration-approved assay performance and the diagnostic accuracy of that assay against a designated reference standard for the stated specific purpose in any laboratory. However, this assumption cannot be applied to the results of laboratory developed tests, because laboratory developed test immunohistochemistry protocol conditions were often different in different laboratories even when the same primary antibody was used, and the protocol was performed on the same automated instrument with the same detection system (e.g., different type and duration of antigen retrieval, primary antibody dilution or incubation time, number of steps of amplification, etc.). When the results of the meta-analysis for laboratory developed tests were suboptimal, but one or more laboratories achieved ≥90% sensitivity and specificity; we cannot exclude the possibility that with appropriate immunohistochemistry protocol modification and assay validation, other laboratories could also achieve optimal results. This contrasts with the use of Food and Drug Administration-approved assays, where no protocol modifications are allowed. Therefore, where the results of laboratory developed tests are excellent, they are representative of what could be achieved by laboratory developed tests rather than that they are generalizable and that they will automatically be achieved in all laboratories.

Results {#Sec10}
=======

Meta-analysis (all tissue models) {#Sec11}
---------------------------------

The number of studies comparing different assays in this meta-analysis was larger than the number of published manuscripts, due to the frequent inclusion of multiple test comparisons in single publication as well as use of different cut-off points for "positive" vs. "negative" test result. Table [1A](#Tab1){ref-type="table"} (non-small cell lung cancer), [1B](#Tab1){ref-type="table"} (all tissue types), 2, and 3 summarize the number of studies that included both candidate and comparator test for a specific, clinically relevant purpose/cut-off point for a specific tissue model. Figures [1](#MOESM5){ref-type="media"}--[13](#MOESM5){ref-type="media"} illustrate forest plots with all studies using non-small cell lung cancer as tissue model (see Supplementary files for Figures [2](#MOESM4){ref-type="media"}--[13](#MOESM4){ref-type="media"}). There was no significant difference in the results when non-small cell lung cancer studies were analyzed separately vs. meta-analysis of all tissue models (compare Table [1A](#Tab1){ref-type="table"} to Table [1B](#Tab2){ref-type="table"}).Table 1ASummary of NSCLC results from all studies (combined estimate of sensitivity and specificity)TPS Cut-offGold StandardCandidate AssayNo. of ComparisonsSensitivity (95% CI)Specificity (95% CI)1%PD-L1 IHC 22C3 pharmDx22C3 LDT110.99 (0.91--1.00)1.00 (0.78--1.00)PD-L1 IHC 28-8 pharmDx180.96 (0.93--0.98)0.84 (0.77--0.88)Ventana PD-L1 (SP263)150.93 (0.90--0.96)0.82 (0.78--0.86)E1L3N LDT130.84 (0.78--0.89)0.92 (0.87--0.95)Ventana PD-L1 (SP142)170.60 (0.53--0.66)0.96 (0.93--0.98)28-8 LDT6See Table BSP142 LDT3See Table CSP263 LDT2See Table C73-10 Assay1See Table CPD-L1 IHC 28-8 pharmDxVentana PD-L1 (SP263)130.91 (0.87--0.94)0.87 (0.80--0.92)PD-L1 IHC 22C3 pharmDx210.88 (0.84--0.92)0.93 (0.91--0.95)28-8 LDT40.82 (0.67--0.91)0.91 (0.82- 0.96)E1L3N LDT110.81 (0.77--0.85)0.96 (0.89--0.99)Ventana PD-L1 (SP142)120.57 (0.50--0.64)0.99 (0.89--1.00)SP142 LDT2See Table CSP263 LDT2See Table C73-10 Assay1See Table CVentana PD-L1 (SP263)PD-L1 IHC 28--8 pharmDx130.93 (0.86--0.97)0.84 (0.79--0.88)PD-L1 IHC 22C3 pharmDx160.84 (0.77--0.89)0.91 (0.85--0.94)E1L3N LDT80.81 (0.75--0.86)0.93 (0.85--0.96)Ventana PD-L1 (SP142)120.57 (0.49--0.64)0.98 (0.97--0.99)28--8 LDT4See Table BSP142 LDT1See Table C73-10 Assay1See Table C22C3 LDT1See Table C50%PD-L1 IHC 22C3 pharmDx22C3 LDT10See Table BPD-L1 IHC 28-8 pharmDx180.94 (0.88--0.97)0.95 (0.92--0.97)28-8 LDT60.95 (0.81--0.99)0.76 (0.67--0.83)Ventana PD-L1 (SP263)150.91 (0.83--0.95)0.92 (0.89--0.95)E1L3N LDT130.76 (0.62--0.86)0.97 (0.95--0.99)Ventana PD-L1 (SP142)160.41 (0.29--0.53)1.00 (0.99--1.00)SP142 LDT3See Table CSP263 LDT1See Table C73-10 Assay1See Table CVentana PD-L1 (SP263)28-8 LDT4See Table BPD-L1 IHC 28-8 pharmDx120.68 (0.54--0.79)0.98 (0.97--0.99)PD-L1 IHC 22C3 pharmDx160.57 (0.45--0.69)0.99 (0.97--1.00)Ventana PD-L1 (SP142)10See Table BSP142 LDT1See Table C22C3 LDT1See Table C73-10 Assay1See Table CTable 1BSummary of results from all studies (combined estimate of sensitivity and specificity)TPS Cut-offGold StandardCandidate AssayNo. of ComparisonsSensitivity (95% CI)Specificity (95% CI)1%PD-L1 IHC 22C3 pharmDx22C3 LDT110.99 (0.91 -1.00)1.00 (0.78--1.00)PD-L1 IHC 28-8 pharmDx210.96 (0.92--0.97)0.84 (0.78--0.88)Ventana PD-L1 (SP263)160.93 (0.88--0.95)0.83 (0.77--0.86)E1L3N LDT140.84 (0.78--0.88)0.94 (0.90--0.96)Ventana PD-L1 (SP142)180.61 (0.55--0.67)0.97 (0.94--0.98)28-8 LDT6See Table BSP142 LDT3See Table CSP263 LDT2See Table C73-10 Assay1See Table CPD-L1 IHC 28-8 pharmDxVentana PD-L1 (SP263)140.90 (0.86--0.94)0.88 (0.82--0.93)PD-L1 IHC 22C3 pharmDx240.88 (0.84--0.91)0.94 (0.92--0.96)28-8 LDT40.82(0.67--0.91)0.91 (0.82--0.96)E1L3N LDT120.80 (0.76--0.84)0.99 (0.94--0.99)Ventana PD-L1 (SP142)130.59 (0.52--0.66)0.99 (0.96--1.00)SP142 LDT2See Table CSP263 LDT2See Table C73-10 Assay1See Table CVentana PD-L1 (SP263)PD-L1 IHC 28-8 pharmDx140.93 (0.86--0.96)0.85 (0.80--0.88)PD-L1 IHC 22C3 pharmDx170.83 (0.76--0.89)0.91 (0.85--0.94)E1L3N LDT90.78 (0.71--0.84)0.93 (0.88--0.96)Ventana PD-L1 (SP142)130.58 (0.51--0.66)0.98 (0.96--0.99)28-8 LDT4See Table BSP142 LDT1See Table C73-10 Assay1See Table C22C3 LDT1See Table C50%PD-L1 IHC 22C3 pharmDx22C3 LDT10See Table BPD-L1 IHC 28-8 pharmDx210.94 (0.88--0.97)0.95 (0.93--0.97)28-8 LDT60.95 (0.81--0.99)0.76 (0.67--0.83)Ventana PD-L1 (SP263)160.92 (0.84--0.96)0.92 (0.90--0.94)E1L3N LDT130.76 (0.62--0.86)0.97 (0.95--0.99)Ventana PD-L1 (SP142)170.42 (0.31--0.54)1.00 (0.99--1.00)SP142 LDT3See Table CSP263 LDT1See Table C73-10 Assay1See Table CVentana PD-L1 (SP263)28-8 LDT4See Table BPD-L1 IHC 28-8 pharmDx130.69 (0.56--0.79)0.98 (0.96--0.99)PD-L1 IHC 22C3 pharmDx170.57 (0.46--0.68)0.99 (0.98--1.00)E1L3N LDT90.36 (0.28--0.44)0.99 (0.93--1.00)Ventana PD-L1 (SP142)10See Table BSP142 LDT1See Table C22C3 LDT1See Table C73-10 Assay1See Table C

Cochran's heterogeneity statistic Q and I^2^ for sensitivity and specificity across all studies are shown in Supplementary Files Table [1](#MOESM3){ref-type="media"}.

Non-converging data {#Sec12}
-------------------

Where the number of studies was less than four or when the data were sparse due to the presence of a zero result in contingency tables (e.g., where sensitivity or specificity was 100%), the models did not converge and did not allow for meta-analysis calculations. As summarized in Tables [2](#Tab3){ref-type="table"} and [3](#Tab4){ref-type="table"}, the latter occurred in a number of studies that had excellent results for both sensitivity and specificity (e.g., 22C3 laboratory developed test compared to PD-L1 IHC 22C3 pharmDx) or specificity only (e.g., Ventana PD-L1 (SP142) compared to Ventana PD-L1 (SP263) and other assays).Table 2Sensitivity and specificity of individual studies for which meta-analysis was not performed because of non-converging dataTPS Cut-offGold Standard AssayCandidate AssayAuthorYearTumor Type\*Sample SizeSensitivitySpecificity50%PD-L1 IHC 22C3 pharmDx22C3 LDTIlie et al.2018L1201.001.00Ilie et al2017L1201.001.00Røge et al.2017L750.931.00Røge et al.2017L751.001.00Neuman et al.2016L411.001.00Ilie et al.2018L1201.001.00Røge et al.2017L751.001.00Ilie et al2017L1201.001.00Neuman et al.2016L411.001.00Munari et al.2018L1830.850.97Hendry et al.2018L5510.841.0050%Ventana PD-L1 (SP263)Ventana PD-L1 (SP142)Adam et al.2018L410.191.00Adam et al.2018L410.111.00Adam et al.2018L410.191.00Adam et al.2018L410.111.00Chan et al.2018L7130.671.00Fujimoto et al.2017L400.331.00Scheel et al.2016L1350.541.00Soo et al.2018L180.331.00Tretiakova et al.2018U1610.460.96Kim et al.2017L970.001.00Cheung et al.2019L540.601.00Hendry et al.2018L3550.331.00Tsao et al.2018L810.281.001%Ventana PD-L1 (SP263)28-8 LDTAdam et al.2018L410.701.00Adam et al.2018L410.731.00Adam et al.2018L410.761.00Adam et al.2018L410.670.9350%Ventana PD-L1 (SP263)28-8 LDTAdam et al.2018L411.000.81Adam et al.2018L411.000.76Adam et al.2018L410.820.67Adam et al.2018L411.000.701%PD-L1 IHC 22C3 pharmDx28-8 LDTAdam et al.2018L410.661.00Adam et al.2018L410.631.00Adam et al.2018L410.681.00Adam et al.2018L320.701.00Adam et al.2018L320.671.00Adam et al.2018L320.731.00\* *L* NSCLC, *U* UCTable 3Sensitivity and specificity of individual studies for which meta-analysis was not performed because of insufficient number of studiesTPS Cut-offGold Standard AssayCandidate AssayAuthorYearTumour TypeSample SizeSensitivitySpecificity1%PD-L1 IHC 22C3 pharmDxSP142 LDTSakane et al.2018TC531.00 (0.90--1.00)0.53 (0.32--0.73)Soo et al.2018NSCLC181.00 (0.77--1.00)0.00 (0.00--0.43)Watanabe et al.2018M320.83 (0.61--0.94)0.86 (0.60--0.96)SP263 LDTSakane et al.2018TC530.97 (0.85--1.0)0.63 (0.41--0.81)Watanabe et al.2018M320.78 (0.55-0.91)0.93 (0.69--0.99)73-10 AssayTsao et al.2018NSCLC811.00 (0.92--1.00)0.53 (0.37--0.68)PD-L1 IHC 28-8 pharmDxSP142 LDTSakane et al.2018TC530.95 (0.84--0.99)0.67 (0.39--0.86)Watanabe et al.2018M320.82 (0.59--0.94)0.80 (0.55--0.93)SP263 LDTSakane et al.2018TC530.90 (0.78--0.96)0.75 (0.47--0.91)Watanabe et al.2018M320.88 (0.66--0.97)1.00 (0.80--1.00)73-10 AssayTsao et al.2018NSCLC810.96 (0.88--0.99)0.63 (0.44--0.79)Ventana PD-L1 (SP263)SP142 LDTSoo et al.2018NSCLC181.00 (0.80--1.00)0.00 (0.00--0.56)73-10 AssayTsao et al.2018NSCLC810.96 (0.87-0.99)0.55 (0.38-0.71)22C3 LDTMunari et al.2018NSCLC1840.66 (0.55--0.76)0.99 (0.95--1.00)50%PD-L1 IHC 22C3 pharmDxSP142 LDTSakane et al.2018TC531.00 (0.85--1.00)0.74 (0.56--0.86)Soo et al.2018NSCLC181.00 (0.34--1.00)0.75 (0.51--0.90)Watanabe et al.2018M320.67 (0.21--0.94)0.66 (0.47--0.45)SP263 LDTSakane et al.2018TC530.82 (0.62--0.93)0.97 (0.84--0.99)Watanabe et al.2018M320.67 (0.21--0.94)0.86 (0.69--0.70)73-10 AssayTsao et al.2018NSCLC811.00 (0.80-1.00)0.82 (0.71--0.89)Ventana PD-L1 (SP263)SP142 LDTSoo et al.2018NSCLC181.00 (0.44--1.00)0.80 (0.55--0.93)22C3 LDTMunari et al.2018NSCLC1840.64 (0.45--0.80)0.99 (0.97--1.00)73-10 AssayTsao et al.2018NSCLC810.94 (0.74--0.99)0.84 (0.73--0.91)*L* NSCLC, *M* mesothelioma, *U* UC, *TC* Thymic Carcinoma

PD-L1 IHC 22C3 pharmDx as reference standard {#Sec13}
--------------------------------------------

The highest diagnostic accuracy was shown for well-designed 22C3 laboratory developed tests compared to PD-L1 IHC pharmDx 22C3. The sensitivity and specificity were both 100% in 8/9 assays for the 50% tumor proportion score cut-off point (Table [2](#Tab3){ref-type="table"}). The results were almost identical, and only slightly less robust for the 1% cut-off (Fig. [1a](#Fig1){ref-type="fig"}, Table [2](#Tab3){ref-type="table"}). Both PD-L1 IHC 28-8 pharmDx and Ventana PD-L1 (SP263) showed acceptable diagnostic accuracy for the 50% cut-off, but both had \<90% specificity against the 1% tumor proportion score cut-off (Fig. [1b--e](#Fig1){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}).Fig. 1**a** 22C3 laboratory developed tests (candidate) vs. PD-L1 IHC pharmDx 22C3 (reference standard) for 1% tumor proportion score cut-off; **b** PD-L1 IHC pharmDx 28-8 (candidate) vs. PD-L1 IHC pharmDx 22C3 (reference standard) for 50% tumor proportion score cut-off; **c** Ventana PD-L1 (SP263) (candidate) vs. PD-L1 IHC pharmDx 22C3 (reference standard) for 50% tumor proportion score cut-off; **d** PD-L1 IHC pharmDx 28-8 (candidate) vs. PD-L1 IHC pharmDx 22C3 (reference standard) for 1% tumor proportion score cut-off; **e** Ventana PD-L1 (SP263) (candidate) vs. PD-L1 IHC pharmDx 22C3 (reference standard) for 1% tumor proportion score cut-off; **f** E1L3N laboratory developed tests (candidate) vs. PD-L1 IHC pharmDx 22C3 (reference standard) for 1% tumor proportion score cut-of; **g** Ventana PD-L1 (SP263) (candidate) vs. PD-L1 IHC pharmDx 28-8 (reference standard) for 1% tumor proportion score cut-off, and **h** PD-L1 IHC pharmDx 22C3 (candidate) vs. PD-L1 IHC pharmDx 28-8 (reference standard) for 1% tumor proportion score cut-off

No other candidate assays reached 90% sensitivity and specificity in the meta-analysis for either the 50% or the 1% tumor proportion score cut-off for PD-L1 IHC 22C3 pharmDx (Table [1](#Tab1){ref-type="table"} and Table [3](#Tab4){ref-type="table"}). Although the overall performance of E1L3N laboratory developed tests in the meta-analysis was not good, E1L3N laboratory developed tests achieved very high sensitivity and specificity in 3 of 12 comparisons (Fig. [1f--h](#Fig1){ref-type="fig"}, Tables [1A](#Tab1){ref-type="table"} and [1B](#Tab2){ref-type="table"}) \[[@CR18], [@CR27]\].

PD-L1 IHC 28-8 pharmDx as reference standard {#Sec14}
--------------------------------------------

The highest results were achieved by the Ventana PD-L1 (SP263) assay; it had acceptable accuracy in the meta-analysis compared to PD-L1 IHC pharm Dx 28-8 at the 1% cut-off (6/12 tests were clinically acceptable) (Fig. [1h](#Fig1){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}). PD-L1 IHC 22C3 pharmDx did not reach ≥ 90% for both sensitivity and specificity in the meta-analysis when compared to PD-L1 IHC pharmDx 28-8 at the 1% cut-off, although 9/19 individual assay comparisons showed sensitivity and specificity of ≥ 90% (Fig. [1i](#Fig1){ref-type="fig"}, Table [1A](#Tab1){ref-type="table"} and [1B](#Tab2){ref-type="table"}).

Ventana PD-L1 (SP263) as reference standard {#Sec15}
-------------------------------------------

No candidate assays achieved required diagnostic accuracy for either the 1% or the 50% cut-off. Most candidate assays achieved acceptable specificity, but the sensitivity was too low for both cut-off points (Tables [1](#Tab1){ref-type="table"}--[3](#Tab4){ref-type="table"}).

Discussion {#Sec16}
==========

The most dominant result of this meta-analysis is that properly designed laboratory developed tests that are performed in an individual immunohistochemistry laboratory (usually a reference laboratory or expert-led laboratory) and are developed for the same purpose as the relevant comparative reference method standard may perform essentially equally to the original Food and Drug Administration-approved assay, but also generally better than the Food and Drug Administration-approved companion diagnostics that were originally developed for different purposes. For example, to identify patients with non-small cell lung cancer for second line therapy with pembrolizumab where PD-L1 IHC pharmDx 22C3 is not available, the results of our study indicate that it is more likely that 22C3 or E1L3N well-developed, fit-for-purpose laboratory developed tests would identify the same patients as positive and/or negative as PD-L1 IHC pharmDx 22C3, rather than Ventana PD-L1 (SP263), Ventana PD-L1 (SP142), or PD-L1 IHC pharmDx 28-8, which were developed for different purposes \[[@CR49]--[@CR53]\].

The accuracy of laboratory developed tests varied in our meta-analysis. 22C3 laboratory developed tests achieved the best results, with both sensitivity and specificity of 100% in 8/9 studies. E1L3N also showed excellent results, but in only 3/12 comparisons. Its success in 3 separate comparisons illustrates that it is possible to develop an acceptable laboratory developed test with this clone and that this antibody can be optimized for clinical applications for which the PD-L1 IHC 22C3 pharmDx was developed. The successful applications of some of the laboratory developed tests reinforce the importance of considering the original purpose of the immunohistochemistry assay, a point emphasized in the ISIMM and IQN Path series of papers entitled "Evolution of Quality Assurance for Immunohistochemistry in the Era of Personalized Medicine" \[[@CR54]--[@CR57]\]. It should be pointed out that our meta-analysis indicates that excellent diagnostic accuracy by laboratory developed tests can be achieved in some laboratories where the laboratory developed tests that were included in this study were originally developed; it remains to be determined whether the same laboratory developed tests would perform the same if more widely tested in different laboratories with different operators using different equipment. External quality assurance including inter-laboratory comparisons, as well as proficiency testing demonstrated that as high as 20--30% or more of the participating laboratories may produce poor results with immunohistochemistry laboratory developed test protocols \[[@CR58]--[@CR62]\]. The success of laboratory developed tests depends on multiple parameters, including which test performance characteristics and which tissue tools may have been used for test development and validation \[[@CR56], [@CR57]\]. In the case of predictive PD-L1 immunohistochemistry assays, recognition and careful definition of the assay purpose according to the 3D approach (Disease, Drug, Diagnostic assay) must also be considered, along with proper selection of the comparative method for determination of diagnostic accuracy of the newly developed candidate test. Several studies have demonstrated that when laboratories follow this approach, they are able to produce excellent results \[[@CR24], [@CR32], [@CR36]--[@CR38]\]. Our study and previously published results do not imply generalizable analytical robustness of laboratory developed tests, whether de novo laboratory developed tests or "kit-derived laboratory developed tests" \[[@CR6], [@CR32]\]. When protocols for laboratory developed tests are shared between laboratories, it is essential that the adopting laboratory conducts initial technical validation, which would increase the likelihood of similar diagnostic accuracy \[[@CR48], [@CR56]\]. However, the purpose of predictive PD-L1 immunohistochemistry assays is not to demonstrate the best signal-to-noise ratio ("nice" and highly sensitive results), but to identify patients that are more likely to benefit from specific drug(s) as demonstrated in clinical trials. Therefore, consideration of this purpose and direct or indirect link with the clinical trial results is always required and it should be considered in test development, test validation, test maintenance, as well as in test performance comparison.

As so far there are no tools to measure analytical sensitivity and specificity of immunohistochemistry assays; this presents a significant problem in assay development, methodology transfer, and daily monitoring of assay performance, as well as direct comparison of assay calibration. The lack of tools that could assess analytical sensitivity and specificity also hinders attempts of immunohistochemistry protocol standardization/harmonization for the PD-L1 assays; without such tools it is not possible to determine the desirable range of analytical sensitivity and specificity of relevance for diagnostic accuracy for any of the PD-L1 assays. This is one cause that we can identify as a potential source of the discrepancy between previously published works that suggested analytical interchangeability of the several Food and Drug Administration-approved PD-L1 assays, but did not necessarily lead to interchangeability based on calculated diagnostic accuracy as shown in our study.

The Ventana PD-L1 (SP263) assay had very high diagnostic sensitivity against all other Food and Drug Administration-approved PD-L1 assays, but its diagnostic specificity was consequently lower. Although several of the studies included in this meta-analysis demonstrated substantial analytical similarity between PD-L1 IHC 22C3 pharmDx, PD-L1 IHC 28-8 pharmDx, and Ventana PD-L1 (SP263), our cumulative results suggest that the diagnostic sensitivity of these various assays (and indirectly their analytical sensitivity) is ordered as follows: PD-L1 IHC 22C3 pharmDx \< PD-L1 IHC 28-8 pharmDx \< Ventana PD-L1 (SP263).

The results of this meta-analysis confirm previous observations that the Ventana PD-L1 (SP142) assay's analytical sensitivity is significantly lower than that of the three other Food and Drug Administration-approved PD-L1 assays and that the diagnostic sensitivity of Ventana PD-L1 (SP142) against PD-L1 IHC 22C3 pharmDx, PD-L1 IHC 28-8 pharmDx, and Ventana PD-L1 (SP263) assays is prohibitively low for both the 1% and the 50% tumor proportion score in non-small cell lung cancer and other tumor models.

Several investigators have evaluated the so-called "interchangeability" of PD-L1 immunohistochemistry assays. The term "interchangeability" has also been used widely by the pharmacological industry to designate drugs that have demonstrated the following characteristics: same amount of the same active ingredients, comparable pharmacokinetics, same clinically significant formulation characteristics, and to be administered in the same way as the drug prescribed \[[@CR63]\]. Basically, interchangeable drugs have the same safety profile and therapeutic effectiveness, as demonstrated in clinical trials \[[@CR64], [@CR65]\]. To apply this term to an immunohistochemistry predictive assay, the manufacturer of the assay, be it industry for a companion/complementary diagnostic or a clinical immunohistochemistry laboratory for an laboratory developed test, would need to prove that the alternative assay will produce the same clinical outcomes. Since none of the assay comparisons were performed in the setting of a prospective clinical trial, this type of evidence is not available for PD-L1 immunohistochemistry assays and therefore, none can be deemed "interchangeable" with another in this same sense of the word. In addition, candidate assays and comparative assays cannot interchange their positions for the purpose of calculations without consequences \[[@CR11]\]. If "interchangeability" would be defined as achieving ≥90% sensitivity and specificity for both the 1% and the 50% tumor proportion score cut-off points, none of the studies in this meta-analysis demonstrated "interchangeability" of the Food and Drug Administration-approved assays PD-L1 IHC 22C3 pharmDx, PD-L1 IHC 28-8 pharmDx, Ventana PD-L1 (SP142), or Ventana PD-L1 (SP263) for each other.

Although they cannot be designated as "interchangeable", the diagnostic accuracy of assays for a specific clinical purpose may be compared. In this manner, the comparison indirectly generates results that can be used to justify clinical usage of assays other than those included in the clinical trials. We employed ≥90% diagnostic sensitivity and ≥90% diagnostic specificity because these values are often used in other settings, including performance of immunohistochemistry assays \[[@CR66]--[@CR68]\]. While it is reasonable that a candidate assay should have at least 90% diagnostic sensitivity, it is unclear whether the required diagnostic specificity should be at the same level, or whether lower specificity could also be clinically acceptable. From the perspective of patient safety, lower diagnostic specificity could potentially be acceptable for those indications/purposes where clinical trials demonstrated that progression free survival, overall survival, and adverse effects in patients with PD-L1-negative tumors treated by immunotherapy are at least comparable if not better to that of conventional chemotherapy.

The strengths of this meta-analysis are the focus on diagnostic accuracy, fit-for-purpose approach, and the access to previously unpublished data from a large number of studies, which all resulted in pooled PD-L1 assay comparison in a way that has not been done before.

The most significant limitation is that this is a meta-analysis of test comparisons where designated reference standards are other tests rather than clinical outcomes. However, to complete a meta-analysis with clinical outcomes may not be possible for many years, if ever. Other limitations of this meta-analysis are that only two cut-off points were assessed (1% and 50%), no assessment for readout that includes inflammatory cells was included, the impact of pathologists' readout as potential source of variation between the studies was not assessed, and it is somewhat uncertain how the results apply to tumors other than non-small cell lung cancer due to the smaller number of such studies.

Conclusions {#Sec17}
===========

The complexity of the PD-L1 immunohistochemistry testing cannot be safely simplified without consideration of the original test purpose. Determination of the diagnostic accuracy and indirect clinical validation of a candidate assay can be achieved by comparing the results of that assay to a previously designated reference standard assay, when direct access to clinical trial data or clinical outcomes is not possible.

Our meta-analysis indicates that {#Sec18}
--------------------------------

1\) Well-designed, fit-for-purpose PD-L1 laboratory developed test candidate assays may achieve higher accuracy than PD-L1 Food and Drug Administration-approved kits that were designed and approved for a different purpose, when both are compared to an appropriate designated reference standard;

2\) More candidate assays achieved ≥ 90% sensitivity and specificity for 50% tumor proportion score cut-off than for 1% tumor proportion score cut-off;

3\) The overall diagnostic sensitivity and specificity analyses indicates that the relative analytical sensitivities of the Food and Drug Administration-approved kits for tumor cell scoring, most specifically in non-small cell lung cancer, are as follows: Ventana PD-L1 (SP142) \<\< PD-L1 IHC 22C3 pharmDx \< PD-L1 IHC 28-8 pharmDx \< Ventana PD-L1 (SP263).
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